Watch the video and download the slides.


Integrating patient preference into treatment decisions for advanced prostate cancer

GU CONNECT expert, Dr. Alicia Morgans provides her perspective on how to integrate patient preference into treatment decisions for advanced prostate cancer.

Watch the video and download the slides.

Hi, my name is Alicia Morgans and I'm a GU Medical Oncologist at Dana-Farber Cancer Institute.

I'm excited to talk with you today about integrating patient preferences into decision making for advanced prostate cancer.

As we know prostate cancer is really a disease spectrum and patients may enter across that spectrum and have different needs and personal preferences at different phases of their disease.

Patient-Centred Care

We as clinicians have to provide patient-centered care that considers these needs across that spectrum and really addresses what a patient is interested in or the symptoms a patient may be experiencing at that particular point in time.

Patient-centered care can improve outcomes like the patient's subjective quality of life and pain control outcomes but can also improve hard outcomes including potentially improving adherence to oral medications that patients must take to improve their cancer control. 

Quality of life that patients experience is comprised of the patient-reported outcomes that patients really provide to reflect their experience in terms of pain control, physical, social or emotional functioning as well as adverse events related to the disease and its treatment.

Of course, all of this must be taken into context in the consideration of this X factor which is patient needs and patient experiences in terms of work obligations or personal obligations, personal anxieties, or preferences.

As we think about patient preferences and incorporating them into decision making, we can consider non-metastatic castration-resistant prostate cancer as an example.

Health-related quality of life

As we consider these clinical trials we can see that health-related quality of life was assessed for all of the trials that assessed treatments for this disease state and importantly all of our options improve or maintain quality of life by patient report.

We also know that the adverse events across the spectrum of the three trials that led to treatments for non-metastatic CRPC were assessed as well and were generally demonstrating good tolerability across the spectrum.

We have to consider, as I also mentioned, those X factors as we think about helping patients through decision making and so this means including conversations about obligations a patient may have personally or professionally, passed experiences that a patient may have or preferences about pain control or disease delivery modality.

Of course, as clinicians we have to work as multi-modal teams and think about how we can get the right treatment to the patient who needs it in the context of his comorbidities that we also need to ensure are managed appropriately. Drug-drug interactions are a key consideration here.

Metastatic castration-resistant prostate cancer (mCRPC) patients

As we think about particularly metastatic castration-resistant prostate cancer patients it is important to remember things that are important to them across the options for treatment that we know at this point improve disease control and hard efficacy outcomes like overall survival and progression-free survival.

In this context pain is often a key concern for patients with metastatic CRPC so providing pain control either through treatment, things like radium for example that can provide both efficacy against the cancer as well as symptom management or using external beam radiation or medications like narcotics or other pain relievers to improve pain control can be really important as we think about patients and their day-to-day quality of life.

Ultimately, we need to work together as a team, work with patients, have shared decisions and really ensure that patients have a voice that is heard in treatment decision making. We can provide the best care for patients as long as we really ensure that we include them in that process.

Please go to GU CONNECT to download these slides for more information.

Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Assoc. Prof. Alicia Morgans has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024

Conference update

Episode

2

of 4

episode
Oncology 
ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Experts
Prof. Shaheenah Dawood
  • clock 3 MIN
  • calendar Jun 2024

Conference update

Episode

3

of 4

episode
Oncology 
ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

Experts
Prof. Dr Peter R. Galle
  • clock 1 MIN
  • calendar Jun 2024